摘要
前列腺癌是欧美国家老年男性最常见恶性肿瘤,早期或局限性前列腺癌可通过根治性手术达到治愈。但随着病程发展,几乎所有初始对雄激素剥夺治疗敏感的前列腺癌患者都将产生激素抵抗,进展为去势抵抗性前列腺癌(castration-resistant prostate cancer,CRPC)。近年,基于程序性死亡受体-1(PD-1)抑制剂帕博利珠单抗(Pembrolizumab)的治疗方案对多种实体瘤效果显著,治疗CRPC也取得初步疗效。本综述旨在总结帕博利珠单抗在CRPC临床试验中的现状及其存在的问题。
Prostate cancer(PCa)is most common among American and European elder males.Despite having the initial effectiveness of radical surgery and androgen deprivation therapy at the preliminary stage,prostate cancer eventually develops into castration-resistant prostate cancer(CRPC),which results in a poor prognosis.In recent years,base-PD-1 inhibitor pembrolizumab has been successfully applied in treating multiple solid tumors,which also has achieved primary efficacy in treating CRPC.This paper summarizes the current status and existing problems of pembrolizumab in the clinical trials of CRPC.
作者
黄威
付伟金
张明津
杨小丽
HUANG Wei;FU Weijin;ZHANG Mingjin;YANG Xiaoli(Guangxi University of Chinese Medicine,Nanning 530200,China;不详)
出处
《实用医学杂志》
CAS
北大核心
2023年第11期1376-1381,共6页
The Journal of Practical Medicine
基金
国家自然科学基金项目(编号:22164007)。
